PYXS

Pyxis Oncology, Inc. Common Stock
Data: 2026-01-30
$1.45
Price
-6.44%
Change
$5.55
52W High
$0.8332
52W Low

Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.

Quick Stats
Jan 30, 2026

52.5

AI Score

HOLD

0.21

Volume Ratio

Mar 17, 2026

Next Earnings

14

+ve Days (30d)

15

-ve Days (30d)

PYXS Stock Summary

Last updated Jan 30, 2026

PYXS is currently trading at $1.45, positioned below its 200-day moving average of $2.05, suggesting bearish momentum. The stock has a 52-week range of $0.8332 to $5.55.

Technical Analysis: The 50-day moving average stands at $2.75, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads 36.454, suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.131, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates PYXS at 52.5/100 with a HOLD recommendation.

PYXS (Pyxis Oncology, Inc. Common Stock) Indicators

Last updated Jan 30, 2026

Indicator Value
RSI(14) 36.454
CMF (20) 0.131
ROC (10) -21.196
ADX (14) 25.285
Indicator Value
MACD (12,26,9) -0.236
AROONOSC (14) -92.857
WILLAMS %R (14) -97.279
MFI (14) 50.133
PYXS Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

PYXS Price vs Max Options Open Interest
PYXS Max Change In Options Open Interest

PYXS Options - Sort by Max open Interest (near term)

30th January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

PYXS Daily Out of Money Options - Sort by Max open Interest (near term)

30th January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

PYXS Daily In the Money Options - Sort by Max open Interest (near term)

30th January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI
Volume Ask PC Delta Vega Volatility % change Track

PYXS Most Active Options by Volume(near term)

30th January 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI
Ask PC Delta Vega Volatility % change Track

Pyxis Oncology, Inc. Common Stock is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

PYXS Moving Averages Analysis

PYXS (Pyxis Oncology, Inc. Common Stock) Simple Moving Averages

Moving Averages are last updated Jan 30, 2026

Days MA
10 1.62
20 1.61
30 1.55
50 2.75
100 2.91
200 2.05

PYXS Fundamental Analysis

P/E (Forward) 0
P/E (Trailing) --
Market Cap ($) 94.0 million
Earnings/Share ($) -1.58
Net Proft Margin (%) 0
Dividend/Share ($) --
EPS Estimate Current Year ($) -1.3111
EPS Estimate Next Year ($) -1.1838
WallStreet Target Price ($) 7.175
Most Recent Quarter